Double-blind randomized study of oral temafloxacin and cefadroxil in patients with mild to moderately severe bacterial skin infections

Article Abstract:

The safety and effectiveness of treatment of mild to moderately severe bacterial skin infections with the antibiotics temafloxacin or cefadroxil were analyzed in 374 patients. The skin infections treated in the study were caused by the bacteria staphylococcus or streptococcus and included superficial skin infections, abscesses, cellulitis (inflammation of the skin), folliculitis (infection of the hair follicles), and infected sweat glands and skin ulcers. Temafloxacin and cefadroxil are members of new group of antibiotics known as fluoroquinolones; these antimicrobial agents have been shown to kill a wide range of bacteria and to work very efficiently in the body, causing minimal adverse effects. The clinical symptoms of the skin infections improved in over 95 percent of the cases treated by either drug. The bacteria were killed in 91 percent of the patients treated with temafloxacin and in 84 percent of the patients treated with cefadroxil. No major problems occurred in the patients after taking either drug. Therefore, it is recommended that temafloxacin can be used to treat mild to moderately severe skin infections caused by staphylococci or streptococci. (Consumer Summary produced by Reliance Medical Information, Inc.)

Antibiotics, Cefadroxil monohydrate, Cefadroxil

---

Systemic antimicrobial therapy in skin and skin structure infections: comparison of temafloxacin and ciprofloxacin

Article Abstract:

The safety and effectiveness of treatment of bacterial infections of the skin and skin structures with fluoroquinolone antibiotics were assessed in 492 patients. Patients received either temafloxacin or ciprofloxacin, and the outcomes of the two treatments were compared. Temafloxacin and ciprofloxacin are members of a new group of antibiotics known as fluoroquinolones. These antibiotics have been shown to kill a wide range of bacteria and to work very efficiently in the body, with minimal adverse effects. Most of the skin infections in this study were superficial skin infections and abscesses usually caused by the bacteria staphylococci. The rate of clinical improvement was 96 percent in those treated with temafloxacin and 99 percent in those treated with ciprofloxacin. The rate of bacterial eradication was 95 percent in those treated with temafloxacin and 93 percent in those treated with ciprofloxacin. The patients experienced very few problems taking the drugs. These results demonstrate that temafloxacin is a safe and effective treatment for bacterial infections of the skin and skin structures. (Consumer Summary produced by Reliance Medical Information, Inc.)

---

Systemic management of cutaneous bacterial infections

Article Abstract:

Bacterial infections of the skin are most effectively treated using systemic antibiotics (absorbed within the body, as opposed to applied on the outer surface of the body). Infections of the skin can be caused by a number of bacteria including group A beta-hemolytic Streptococcus and Staphylococcus aureus. Bacterial skin infections are currently treated with beta-lactam antibiotics, tetracycline, and erythromycin. However, bacteria that are resistant to and are not killed by these drugs are evolving. During the last 10 years, skin infections have also been treated with a new group of antibiotics known as the fluoroquinolones; ciprofloxacin, enoxacin, ofloxacin and temafloxacin are members of the fluoroquinolone group. These antibiotics kill various types of bacteria and work very effectively in the body, causing few adverse effects. Consequently, the use of fluoroquinolones, administered by mouth, is recommended for the treatment of bacterial skin infections. (Consumer Summary produced by Reliance Medical Information, Inc.)

Similar abstracts:

• Abstracts: In vitro activity of temafloxacin against gram-negative bacteria: an overview. In vitro activity of temafloxacin against gram-positive cocci including methicillin-resistant Staphylococcus aureus
• Abstracts: Efficacy of temafloxacin versus ciprofloxacin or amoxicillin in lower respiratory tract infections in smokers and the elderly
• Abstracts: Brief report: pharmacokinetics of ciprofloxacin in young (healthy volunteers) and elderly patients, and concentrations in prostatic fluid, seminal fluid, and prostatic adenoma tissue following intravenous administration

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.